Nasdaq
$30.65▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.12BShares out 69.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 1d agoAfter-hours26.10.24 08:354Ownership#●●●#●●●
Alamar Biosciences, Inc.
Major investors affiliated with Qiming Venture Partners have reported changes in their beneficial ownership of Alamar Biosciences, Inc. This filing is a Form 4 statement regarding insider equity holdings.…more
$30.65+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 08:154Ownership
Alamar Biosciences, Inc.
Investment entities affiliated with Qiming Venture Partners, a major shareholder of Alamar Biosciences, have filed a Form 4 to report changes in their beneficial ownership. This filing reflects shifts in the equity structure held by insiders and major shareholders, which investors should monitor.…more
$30.65+0.00%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 05:304Ownership
Alamar Biosciences, Inc.
Affiliated investment entities of Qiming Venture Partners have filed a report regarding their beneficial ownership of Alamar Biosciences, Inc. shares. This filing serves as a routine disclosure of changes in insider holdings.…more
$30.65+0.00%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8After-hours26.10.09 05:05#●●●#●●●
Alamar Biosciences to Report Q3 2026 Financial Results on November 3
Alamar Biosciences announced that it will report its financial results for the third quarter of 2026 after the market closes on November 3. A conference call will be held following the release to discuss the company's performance.…more
$30.65+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5After-hours26.10.06 05:05
●●●●●●●● ●●●●● ●●●●●●
Alamar Biosciences has appointed former Grail CEO Bob Ragusa to its board of directors and added new members to its leadership team. These appointments are intended to support the company's growth and the scaling of its proteomics platform.…more
$30.65+0.00%vs prev close - 9.25Overnight26.09.25 16:19
●●●●●●●● ●●●●● ●●●●●●
Alamar Biosciences' precision proteomics platform was utilized in a Lancet Neurology study regarding Alzheimer's patients. The technology helped identify distinct biological responses in patients undergoing treatment with lecanemab.…more
$30.65+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report